|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
|
relating to the criminal penalties for the possession of certain |
|
tetrahydrocannabinols under the Texas Controlled Substances Act. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. Sections 481.002(5) and (6), Health and Safety |
|
Code, are amended to read as follows: |
|
(5) "Controlled substance" means a substance, |
|
including a drug, an adulterant, and a dilutant, listed in |
|
Schedules I through V or Penalty Group 1, 1-A, 2, 2-A, 2-B, 3, or 4. |
|
The term includes the aggregate weight of any mixture, solution, or |
|
other substance containing a controlled substance. The term does |
|
not include hemp, as defined by Section 121.001, Agriculture Code, |
|
or the tetrahydrocannabinols in hemp. |
|
(6) "Controlled substance analogue" means: |
|
(A) a substance with a chemical structure |
|
substantially similar to the chemical structure of a controlled |
|
substance in Schedule I or II or Penalty Group 1, 1-A, 2, [or] 2-A, |
|
or 2-B; or |
|
(B) a substance specifically designed to produce |
|
an effect substantially similar to, or greater than, the effect of a |
|
controlled substance in Schedule I or II or Penalty Group 1, 1-A, 2, |
|
[or] 2-A, or 2-B. |
|
SECTION 2. Section 481.103(a), Health and Safety Code, is |
|
amended to read as follows: |
|
(a) Penalty Group 2 consists of: |
|
(1) any quantity of the following hallucinogenic |
|
substances, their salts, isomers, and salts of isomers, unless |
|
specifically excepted, if the existence of these salts, isomers, |
|
and salts of isomers is possible within the specific chemical |
|
designation: |
|
5-(2-aminopropyl)benzofuran (5-APB); |
|
6-(2-aminopropyl)benzofuran (6-APB); |
|
5-(2-aminopropyl)-2,3-dihydrobenzofuran |
|
(5-APDB); |
|
6-(2-aminopropyl)-2,3-dihydrobenzofuran |
|
(6-APDB); |
|
5-(2-aminopropyl)indole (5-IT,5-API); |
|
6-(2-aminopropyl)indole (6-IT,6-API); |
|
1-(benzofuran-5-yl)-N-methylpropan-2-amine |
|
(5-MAPB); |
|
1-(benzofuran-6-yl)-N-methylpropan-2-amine |
|
(6-MAPB); |
|
Benzothiophenylcyclohexylpiperidine (BTCP); |
|
8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- |
|
4-ethanamine (trade or other name: Bromo-DragonFLY); |
|
Desoxypipradrol (2-benzhydrylpiperidine); |
|
2, 5-dimethoxyamphetamine (some trade or other |
|
names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA); |
|
Diphenylprolinol (diphenyl(pyrrolidin-2-yl) |
|
methanol, D2PM); |
|
Dronabinol (synthetic) in sesame oil and |
|
encapsulated in a soft gelatin capsule in a U.S. Food and Drug |
|
Administration approved drug product (some trade or other names for |
|
Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- |
|
trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- |
|
(trans)- tetrahydrocannabinol); |
|
Ethylamine Analog of Phencyclidine (some trade or |
|
other names: N-ethyl-1-phenylcyclohexylamine, (1- |
|
phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, |
|
cyclohexamine, PCE); |
|
2-ethylamino-2-(3-methoxyphenyl)cyclohexanone |
|
(trade or other name: methoxetamine); |
|
Ibogaine (some trade or other names: 7-Ethyl-6, |
|
6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- |
|
pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.); |
|
5-iodo-2-aminoindane (5-IAI); |
|
Mescaline; |
|
5-methoxy-3, 4-methylenedioxy amphetamine; |
|
4-methoxyamphetamine (some trade or other |
|
names: 4-methoxy-alpha-methylphenethylamine; |
|
paramethoxyamphetamine; PMA); |
|
4-methoxymethamphetamine (PMMA); |
|
2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone |
|
(some trade and other names: 2-MeO-ketamine; methoxyketamine); |
|
1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, |
|
PPMP); |
|
4-methyl-2, 5-dimethoxyamphetamine (some trade |
|
and other names: 4-methyl-2, 5-dimethoxy-alpha- |
|
methylphenethylamine; "DOM"; "STP"); |
|
3,4-methylenedioxy methamphetamine (MDMA, MDM); |
|
3,4-methylenedioxy amphetamine; |
|
3,4-methylenedioxy N-ethylamphetamine (Also |
|
known as N-ethyl MDA); |
|
5,6-methylenedioxy-2-aminoindane (MDAI); |
|
Nabilone (Another name for nabilone: (+)-trans- |
|
3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, |
|
6-dimethyl-9H-dibenzo[b,d] pyran-9-one; |
|
N-benzylpiperazine (some trade or other |
|
names: BZP; 1-benzylpiperazine); |
|
N-ethyl-3-piperidyl benzilate; |
|
N-hydroxy-3,4-methylenedioxyamphetamine (Also |
|
known as N-hydroxy MDA); |
|
4-methylaminorex; |
|
N-methyl-3-piperidyl benzilate; |
|
Parahexyl (some trade or other names: 3-Hexyl-1- |
|
hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] |
|
pyran; Synhexyl); |
|
1-Phenylcyclohexylamine; |
|
1-Piperidinocyclohexanecarbonitrile (PCC); |
|
Pyrrolidine Analog of Phencyclidine (some trade |
|
or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP); |
|
[Tetrahydrocannabinols, other than marihuana, and |
|
synthetic equivalents of the substances contained in the plant, or |
|
in the resinous extractives of Cannabis, or synthetic substances, |
|
derivatives, and their isomers with similar chemical structure and |
|
pharmacological activity such as: |
|
[delta-1 cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
[delta-6 cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
[delta-3, 4 cis or trans |
|
tetrahydrocannabinol, and its optical isomers; or |
|
[compounds of these structures, regardless |
|
of numerical designation of atomic positions, since nomenclature of |
|
these substances is not internationally standardized;] |
|
Thiophene Analog of Phencyclidine (some trade or |
|
other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl |
|
Analog of Phencyclidine; TPCP, TCP); |
|
1-pyrrolidine (some trade or other name: TCPy); |
|
1-(3-trifluoromethylphenyl)piperazine (trade or |
|
other name: TFMPP); and |
|
3,4,5-trimethoxy amphetamine; |
|
(2) Phenylacetone (some trade or other |
|
names: Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl |
|
ketone); |
|
(3) unless specifically excepted or unless listed in |
|
another Penalty Group, a material, compound, mixture, or |
|
preparation that contains any quantity of the following substances |
|
having a potential for abuse associated with a depressant or |
|
stimulant effect on the central nervous system: |
|
Aminorex (some trade or other |
|
names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5- |
|
phenyl-2-oxazolamine); |
|
Amphetamine, its salts, optical isomers, and |
|
salts of optical isomers; |
|
Cathinone (some trade or other names: 2-amino-1- |
|
phenyl-1-propanone, alpha-aminopropiophenone, 2- |
|
aminopropiophenone); |
|
Etaqualone and its salts; |
|
Etorphine Hydrochloride; |
|
Fenethylline and its salts; |
|
Lisdexamfetamine, including its salts, isomers, |
|
and salts of isomers; |
|
Mecloqualone and its salts; |
|
Methaqualone and its salts; |
|
Methcathinone (some trade or other names: 2- |
|
methylamino-propiophenone; alpha-(methylamino)propriophenone; |
|
2-(methylamino)-1-phenylpropan-1-one; alpha-N- |
|
methylaminopropriophenone; monomethylpropion; ephedrone, N- |
|
methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR |
|
1431); |
|
N-Ethylamphetamine, its salts, optical isomers, |
|
and salts of optical isomers; and |
|
N,N-dimethylamphetamine (some trade or other |
|
names: N,N,alpha-trimethylbenzeneethanamine; |
|
N,N,alpha-trimethylphenethylamine), its salts, optical isomers, |
|
and salts of optical isomers; |
|
(4) any compound structurally derived from |
|
2-aminopropanal by substitution at the 1-position with any |
|
monocyclic or fused-polycyclic ring system, including: |
|
(A) compounds further modified by: |
|
(i) substitution in the ring system to any |
|
extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or |
|
halide substituents), whether or not further substituted in the |
|
ring system by other substituents; |
|
(ii) substitution at the 3-position with an |
|
alkyl substituent; or |
|
(iii) substitution at the 2-amino nitrogen |
|
atom with alkyl, benzyl, dialkyl, or methoxybenzyl groups, or |
|
inclusion of the 2-amino nitrogen atom in a cyclic structure; and |
|
(B) by example, compounds such as: |
|
4-Methylmethcathinone (Also known as |
|
Mephedrone); |
|
3,4-Dimethylmethcathinone (Also known as |
|
3,4-DMMC); |
|
3-Fluoromethcathinone (Also known as 3-FMC); |
|
4-Fluoromethcathinone (Also known as |
|
Flephedrone); |
|
3,4-Methylenedioxy-N-methylcathinone (Also |
|
known as Methylone); |
|
3,4-Methylenedioxypyrovalerone (Also known |
|
as MDPV); |
|
alpha-Pyrrolidinopentiophenone (Also known |
|
as alpha-PVP); |
|
Naphthylpyrovalerone (Also known as |
|
Naphyrone); |
|
alpha-Methylamino-valerophenone (Also known |
|
as Pentedrone); |
|
beta-Keto-N-methylbenzodioxolylpropylamine |
|
(Also known as Butylone); |
|
beta-Keto-N-methylbenzodioxolylpentanamine |
|
(Also known as Pentylone); |
|
beta-Keto-Ethylbenzodioxolylbutanamine |
|
(Also known as Eutylone); and |
|
3,4-methylenedioxy-N-ethylcathinone (Also |
|
known as Ethylone); |
|
(5) any compound structurally derived from tryptamine |
|
(3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine: |
|
(A) by modification in any of the following ways: |
|
(i) by substitution at the amine nitrogen |
|
atom of the sidechain to any extent with alkyl or alkenyl groups or |
|
by inclusion of the amine nitrogen atom of the side chain (and no |
|
other atoms of the side chain) in a cyclic structure; |
|
(ii) by substitution at the carbon atom |
|
adjacent to the nitrogen atom of the side chain (alpha-position) |
|
with an alkyl or alkenyl group; |
|
(iii) by substitution in the 6-membered |
|
ring to any extent with alkyl, alkoxy, haloalkyl, thioaklyl, |
|
alkylenedioxy, or halide substituents; or |
|
(iv) by substitution at the 2-position of |
|
the tryptamine ring system with an alkyl substituent; and |
|
(B) including: |
|
(i) ethers and esters of the controlled |
|
substances listed in this subdivision; and |
|
(ii) by example, compounds such as: |
|
alpha-ethyltryptamine; |
|
alpha-methyltryptamine; |
|
Bufotenine (some trade and other names: |
|
3-(beta-Dimethylaminoethyl)-5-hydroxyindole; |
|
3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; |
|
5-hydroxy-N, N- dimethyltryptamine; mappine); |
|
Diethyltryptamine (some trade and |
|
other names: N, N-Diethyltryptamine, DET); |
|
Dimethyltryptamine (trade or other |
|
name: DMT); |
|
5-methoxy-N, N-diisopropyltryptamine |
|
(5-MeO-DiPT); |
|
O-Acetylpsilocin (Trade or other name: |
|
4-Aco-DMT); |
|
Psilocin; and |
|
Psilocybin; |
|
(6) 2,5-Dimethoxyphenethylamine and any compound |
|
structurally derived from 2,5-Dimethoxyphenethylamine by |
|
substitution at the 4-position of the phenyl ring to any extent |
|
(including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide |
|
substituents), including, by example, compounds such as: |
|
4-Bromo-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-B); |
|
4-Chloro-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-C); |
|
2,5-Dimethoxy-4-methylphenethylamine (trade or |
|
other name: 2C-D); |
|
4-Ethyl-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-E); |
|
4-Iodo-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-I); |
|
2,5-Dimethoxy-4-nitrophenethylamine (trade or |
|
other name: 2C-N); |
|
2,5-Dimethoxy-4-(n)-propylphenethylamine (trade |
|
or other name: 2C-P); |
|
4-Ethylthio-2,5-dimethoxyphenethylamine (trade |
|
or other name: 2C-T-2); |
|
4-Isopropylthio-2,5-dimethoxyphenethylamine |
|
(trade or other name: 2C-T-4); and |
|
2,5-Dimethoxy-4-(n)-propylthiophenethylamine |
|
(trade or other name: 2C-T-7); and |
|
(7) 2,5-Dimethoxyamphetamine and any compound |
|
structurally derived from 2,5-Dimethoxyamphetamine by substitution |
|
at the 4-position of the phenyl ring to any extent (including alkyl, |
|
alkoxy, alkylenedioxy, haloalkyl, or halide substituents), |
|
including, by example, compounds such as: |
|
4-Ethylthio-2,5-dimethoxyamphetamine (trade or |
|
other name: Aleph-2); |
|
4-Isopropylthio-2,5-dimethoxyamphetamine (trade |
|
or other name: Aleph-4); |
|
4-Bromo-2,5-dimethoxyamphetamine (trade or other |
|
name: DOB); |
|
4-Chloro-2,5-dimethoxyamphetamine (trade or |
|
other name: DOC); |
|
2,5-Dimethoxy-4-ethylamphetamine (trade or other |
|
name: DOET); |
|
4-Iodo-2,5-dimethoxyamphetamine (trade or other |
|
name: DOI); |
|
2,5-Dimethoxy-4-methylamphetamine (trade or |
|
other name: DOM); |
|
2,5-Dimethoxy-4-nitroamphetamine (trade or other |
|
name: DON); |
|
4-Isopropyl-2,5-dimethoxyamphetamine (trade or |
|
other name: DOIP); and |
|
2,5-Dimethoxy-4-(n)-propylamphetamine (trade or |
|
other name: DOPR). |
|
SECTION 3. Subchapter D, Chapter 481, Health and Safety |
|
Code, is amended by adding Section 481.1032 to read as follows: |
|
Sec. 481.1032. PENALTY GROUP 2-B. (a) Penalty Group 2-B |
|
consists of any quantity of the following substances, their salts, |
|
isomers, and salts of isomers, unless specifically excepted, if the |
|
existence of these salts, isomers, and salts of isomers is possible |
|
within the specific chemical designation: |
|
Tetrahydrocannabinols, other than marihuana, and |
|
synthetic equivalents of the substances contained in the plant, or |
|
in the resinous extractives of Cannabis, or synthetic substances, |
|
derivatives, and their isomers with similar chemical structure and |
|
pharmacological activity such as: |
|
delta-1 cis or trans tetrahydrocannabinol, and |
|
their optical isomers; |
|
delta-6 cis or trans tetrahydrocannabinol, and |
|
their optical isomers; |
|
delta-3, 4 cis or trans tetrahydrocannabinol, and |
|
its optical isomers; or |
|
compounds of these structures, regardless of |
|
numerical designation of atomic positions, since nomenclature of |
|
these substances is not internationally standardized. |
|
(b) For the purposes of this section, the term "isomer" |
|
includes an optical, position, or geometric isomer. |
|
SECTION 4. Section 481.106, Health and Safety Code, is |
|
amended to read as follows: |
|
Sec. 481.106. CLASSIFICATION OF CONTROLLED SUBSTANCE |
|
ANALOGUE. For the purposes of the prosecution of an offense under |
|
this subchapter involving the manufacture, delivery, or possession |
|
of a controlled substance, Penalty Groups 1, 1-A, 2, [and] 2-A, and |
|
2-B include a controlled substance analogue that: |
|
(1) has a chemical structure substantially similar to |
|
the chemical structure of a controlled substance listed in the |
|
applicable penalty group; or |
|
(2) is specifically designed to produce an effect |
|
substantially similar to, or greater than, a controlled substance |
|
listed in the applicable penalty group. |
|
SECTION 5. The heading to Section 481.113, Health and |
|
Safety Code, is amended to read as follows: |
|
Sec. 481.113. OFFENSE: MANUFACTURE OR DELIVERY OF SUBSTANCE |
|
IN PENALTY GROUP 2, [OR] 2-A, OR 2-B. |
|
SECTION 6. Section 481.113(a), Health and Safety Code, is |
|
amended to read as follows: |
|
(a) Except as authorized by this chapter, a person commits |
|
an offense if the person knowingly manufactures, delivers, or |
|
possesses with intent to deliver a controlled substance listed in |
|
Penalty Group 2, [or] 2-A, or 2-B. |
|
SECTION 7. The heading to Section 481.1161, Health and |
|
Safety Code, is amended to read as follows: |
|
Sec. 481.1161. OFFENSE: POSSESSION OF SUBSTANCE IN PENALTY |
|
GROUP 2-A OR 2-B. |
|
SECTION 8. Section 481.1161(a), Health and Safety Code, is |
|
amended to read as follows: |
|
(a) Except as authorized by this chapter, a person commits |
|
an offense if the person knowingly possesses a controlled substance |
|
listed in Penalty Group 2-A or 2-B, unless the person obtained the |
|
substance directly from or under a valid prescription or order of a |
|
practitioner acting in the course of professional practice. |
|
SECTION 9. Section 481.122(a), Health and Safety Code, is |
|
amended to read as follows: |
|
(a) A person commits an offense if the person knowingly |
|
delivers a controlled substance listed in Penalty Group 1, 1-A, 2, |
|
2-B, or 3 or knowingly delivers marihuana and the person delivers |
|
the controlled substance or marihuana to a person: |
|
(1) who is a child; |
|
(2) who is enrolled in a public or private primary or |
|
secondary school; or |
|
(3) who the actor knows or believes intends to deliver |
|
the controlled substance or marihuana to a person described by |
|
Subdivision (1) or (2). |
|
SECTION 10. Sections 551.003(11) and (12), Occupations |
|
Code, are amended to read as follows: |
|
(11) "Controlled substance" means a substance, |
|
including a drug: |
|
(A) listed in Schedule I, II, III, IV, or V, as |
|
established by the commissioner of public health under Chapter 481, |
|
Health and Safety Code, or in Penalty Group 1, 1-A, 2, 2-B, 3, or 4, |
|
Chapter 481; or |
|
(B) included in Schedule I, II, III, IV, or V of |
|
the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 |
|
U.S.C. Section 801 et seq.). |
|
(12) "Dangerous drug" means a drug or device that: |
|
(A) is not included in Penalty Group 1, 2, 2-B, 3, |
|
or 4, Chapter 481, Health and Safety Code, and is unsafe for |
|
self-medication; or |
|
(B) bears or is required to bear the legend: |
|
(i) "Caution: federal law prohibits |
|
dispensing without prescription" or "Rx only" or another legend |
|
that complies with federal law; or |
|
(ii) "Caution: federal law restricts this |
|
drug to use by or on the order of a licensed veterinarian." |
|
SECTION 11. The change in law made by this Act applies only |
|
to an offense committed on or after the effective date of this Act. |
|
An offense committed before the effective date of this Act is |
|
governed by the law in effect when the offense was committed, and |
|
the former law is continued in effect for that purpose. For purposes |
|
of this section, an offense was committed before the effective date |
|
of this Act if any element of the offense occurred before that date. |
|
SECTION 12. This Act takes effect September 1, 2021. |
|
|
|
* * * * * |